User:Ivan E. Wang/Sandbox 1
From Proteopedia
Contents |
Introduction to the RPE65
| |||||||||||
Structure and Activity
Structural Analysis of RPE65
(PLACEHOLDER)
Enzymatic Activity of RPE65
(PLACEHOLDER)
Figure 2: The canonical Visual Cycle in Humans [1]
Protein-Ligand Interaction
Endogenous Ligand
(PLACEHOLDER)
Exogenous Ligand
(R)-Emixustat (ACU-4429)
| |||||||||||
(S)-Emixustat
| |||||||||||
R/S Enantiomers Differences
(PLACEHOLDER)
Disease Implications
(PLACEHOLDER)
Medical Relevance
(PLACEHOLDER)
This is a sample scene created with SAT to by Group, and another to make of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
References
- ↑ Shin Y, Moiseyev G, Petrukhin K, Cioffi CL, Muthuraman P, Takahashi Y, Ma JX. A novel RPE65 inhibitor CU239 suppresses visual cycle and prevents retinal degeneration. Biochim Biophys Acta Mol Basis Dis. 2018 Jul;1864(7):2420-2429. doi:, 10.1016/j.bbadis.2018.04.014. Epub 2018 Apr 21. PMID:29684583 doi:http://dx.doi.org/10.1016/j.bbadis.2018.04.014
